换一批
换一批Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
作者：
Guy,de Bruyn [1]
;
Joyce,Wang [2]
;
Annie,Purvis [3]
;
Martin Sanchez,Ruiz [4]
;
Haritha,Adhikarla [1]
;
Saad,Alvi [5]
;
Matthew I,Bonaparte [1]
;
Daniel,Brune [6]
;
Agustin,Bueso [7]
;
Richard M,Canter [1]
;
Maria Angeles,Ceregido [8]
;
Sachin,Deshmukh [9]
;
David,Diemert [10]
;
Adam,Finn [11]
;
Remi,Forrat [12]
;
Bo,Fu [1]
;
Julie,Gallais [12]
;
Paul,Griffin [13]
;
Marie-Helene,Grillet [14]
;
Owen,Haney [15]
;
Jeffrey A,Henderson [1]
;
Marguerite,Koutsoukos [16]
;
Odile,Launay [8]
;
Federico Martinon,Torres [17]
;
Roger,Masotti [18]
;
Nelson L,Michael [19]
;
Juliana,Park [20]
;
Doris Maribel,Rivera-Medina [1]
;
Natalya,Romanyak [21]
;
Chris,Rook [22]
;
Lode,Schuerman [23]
;
Lawrence D,Sher [1]
;
Fernanda,Tavares-Da-Silva [24]
;
Ashley,Whittington [8]
;
Roman M,Chicz [25]
;
Sanjay,Gurunathan [8]
;
Stephen,Savarino [26]
;
Saranya,Sridhar [3]
;
VAT00002 booster cohorts study team [1]
作者单位：
Sanofi, Swiftwater, PA, USA.
[1]
Sanofi, Chengdu, China.
[2]
Sanofi, Waltham, MA, USA.
[3]
Sanofi, Paris, France.
[4]
Chicago Clinical Research Institute, IL, USA.
[5]
Optimal Research, Peoria, IL, USA.
[6]
Demedica, San Pedro Sula, Honduras.
[7]
GSK, Wavre, Belgium.
[8]
Griffith University, Australia.
[9]
School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
[10]
Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
[11]
Sanofi, Marcy l'Etoile, France.
[12]
Mater Health, Brisbane, Queensland, Australia.
[13]
The University of Queensland, Brisbane, Queensland, Australia.
[14]
Sanofi, Lyon, France.
[15]
Black Hills Center for American Indian Health, SD, USA.
[16]
Université Paris Cité; Inserm, F-CRIN I REIVAC, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
[17]
Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain.
[18]
Genetics, Vaccines- Infectious Diseases and Pediatrics Research Group GENVIP, Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
[19]
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
[20]
Walter Reed Army Institute of Research, Silver Spring, MD, USA.
[21]
Sanofi, Sydney, Australia.
[22]
INVERIME S.A, Tegucigalpa, Honduras.
[23]
Cmax, Adelaide, Australia.
[24]
Peninsula Research Associates, Rolling Hills Estates, CA, USA.
[25]
London North West University Healthcare NHS Trust, London, UK.
[26]
Sanofi, Reading, UK.
[27]
DOI
10.1016/j.eclinm.2023.102109
PMID
37533419
发布时间
2023-09-25
- 浏览0
EClinicalMedicine
2023年62卷
102109页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
